152 related articles for article (PubMed ID: 34117911)
1. Inter-center agreement of mRECIST in transplanted patients for hepatocellular carcinoma.
Vicentin I; Mosconi C; Garanzini E; Sposito C; Serenari M; Buscemi V; Verna M; Spreafico C; Golfieri R; Mazzaferro V; De Carlis L; Cescon M; Ercolani G; Vanzulli A; Cucchetti A
Eur Radiol; 2021 Dec; 31(12):8903-8912. PubMed ID: 34117911
[TBL] [Abstract][Full Text] [Related]
2. Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602.
Sato Y; Watanabe H; Sone M; Onaya H; Sakamoto N; Osuga K; Takahashi M; Arai Y;
Ups J Med Sci; 2013 Mar; 118(1):16-22. PubMed ID: 23167460
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of HCC response to locoregional therapy: Validation of MRI-based response criteria versus explant pathology.
Gordic S; Corcuera-Solano I; Stueck A; Besa C; Argiriadi P; Guniganti P; King M; Kihira S; Babb J; Thung S; Taouli B
J Hepatol; 2017 Dec; 67(6):1213-1221. PubMed ID: 28823713
[TBL] [Abstract][Full Text] [Related]
4. Radiological response and inflammation scores predict tumour recurrence in patients treated with transarterial chemoembolization before liver transplantation.
Nicolini D; Agostini A; Montalti R; Mocchegiani F; Mincarelli C; Mandolesi A; Robertson NL; Candelari R; Giovagnoni A; Vivarelli M
World J Gastroenterol; 2017 May; 23(20):3690-3701. PubMed ID: 28611522
[TBL] [Abstract][Full Text] [Related]
5. Correlation of tumor response on computed tomography with pathological necrosis in hepatocellular carcinoma treated by chemoembolization before liver transplantation.
Dioguardi Burgio M; Ronot M; Bruno O; Francoz C; Paradis V; Castera L; Durand F; Soubrane O; Vilgrain V
Liver Transpl; 2016 Nov; 22(11):1491-1500. PubMed ID: 27543821
[TBL] [Abstract][Full Text] [Related]
6. mRECIST criteria and contrast-enhanced US for the assessment of the response of hepatocellular carcinoma to transarterial chemoembolization.
Moschouris H; Malagari K; Papadaki MG; Kornezos I; Stamatiou K; Anagnostopoulos A; Chatzimichael K; Kelekis N
Diagn Interv Radiol; 2014; 20(2):136-42. PubMed ID: 24317334
[TBL] [Abstract][Full Text] [Related]
7. Reproducibility of mRECIST in Measurement and Response Assessment for Hepatocellular Carcinoma Treated by Transarterial Chemoembolization.
Choi MH; Park GE; Oh SN; Park MY; Rha SE; Lee YJ; Jung SE; Choi JI
Acad Radiol; 2018 Nov; 25(11):1363-1373. PubMed ID: 29555570
[TBL] [Abstract][Full Text] [Related]
8. LI-RADS treatment response algorithm after first-line DEB-TACE: reproducibility and prognostic value at initial post-treatment CT/MRI.
Pirasteh A; Sorra EA; Marquez H; Sibley RC; Fielding JR; Vij A; Rich NE; Arroyo A; Yopp AC; Khatri G; Singal AG; Yokoo T
Abdom Radiol (NY); 2021 Aug; 46(8):3708-3716. PubMed ID: 33755735
[TBL] [Abstract][Full Text] [Related]
9. Optimal measurement modality and method for evaluation of responses to transarterial chemoembolization of hepatocellular carcinoma based on enhancement criteria.
Shim JH; Han S; Shin YM; Yu E; Park W; Kim KM; Lim YS; Lee HC
J Vasc Interv Radiol; 2013 Mar; 24(3):316-25. PubMed ID: 23312990
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis.
Vincenzi B; Di Maio M; Silletta M; D'Onofrio L; Spoto C; Piccirillo MC; Daniele G; Comito F; Maci E; Bronte G; Russo A; Santini D; Perrone F; Tonini G
PLoS One; 2015; 10(7):e0133488. PubMed ID: 26230853
[TBL] [Abstract][Full Text] [Related]
11. Interreader and inter-test agreement in assessing treatment response following transarterial embolization for hepatocellular carcinoma.
Donati OF; Do RK; Hötker AM; Katz SS; Zheng J; Moskowitz CS; Beattie C; Brown KT
Eur Radiol; 2015 Sep; 25(9):2779-88. PubMed ID: 25850892
[TBL] [Abstract][Full Text] [Related]
12. Optimal imaging criteria and modality to determine Milan criteria for the prediction of post-transplant HCC recurrence after locoregional treatment.
Seo N; Joo DJ; Park MS; Kim SS; Shin HJ; Chung YE; Choi JY; Kim MS; Kim MJ
Eur Radiol; 2023 Jan; 33(1):501-511. PubMed ID: 35821427
[TBL] [Abstract][Full Text] [Related]
13. Modified RECIST to assess tumor response after transarterial chemoembolization of hepatocellular carcinoma: CT-pathologic correlation in 178 liver explants.
Bargellini I; Bozzi E; Campani D; Carrai P; De Simone P; Pollina L; Cioni R; Filipponi F; Bartolozzi C
Eur J Radiol; 2013 May; 82(5):e212-8. PubMed ID: 23332890
[TBL] [Abstract][Full Text] [Related]
14. Follow-up of multicentric HCC according to the mRECIST criteria: role of 320-Row CT with semi-automatic 3D analysis software for evaluating the response to systemic therapy.
Telegrafo M; Dilorenzo G; Di Giovanni G; Cornacchia I; Stabile Ianora AA; Cornacchia I; Stabile Ianora AA; Angelelli G; Moschetta M
G Chir; 2017; 37(5):206-210. PubMed ID: 28098056
[TBL] [Abstract][Full Text] [Related]
15. Inter-observer variability of response evaluation criteria for hepatocellular carcinoma treated with chemoembolization.
Kim BK; Kim KA; Kim MJ; Park JY; Kim DY; Ahn SH; Han KH; Kim SU; Park MS
Dig Liver Dis; 2015 Aug; 47(8):682-8. PubMed ID: 25977216
[TBL] [Abstract][Full Text] [Related]
16. Comparison of α-Fetoprotein Criteria and Modified Response Evaluation Criteria in Solid Tumors for the Prediction of Overall Survival of Patients with Hepatocellular Carcinoma after Transarterial Chemoembolization.
Zhang YQ; Jiang LJ; Wen J; Liu DM; Huang GH; Wang Y; Fan WZ; Li JP
J Vasc Interv Radiol; 2018 Dec; 29(12):1654-1661. PubMed ID: 30396842
[TBL] [Abstract][Full Text] [Related]
17. Radiological appearance of hepatocellular carcinoma predicts the response to trans-arterial chemoembolization in patients undergoing liver transplantation.
Zhang W; Xu AH; Wang W; Wu YH; Sun QL; Shu C
BMC Cancer; 2019 Nov; 19(1):1041. PubMed ID: 31690274
[TBL] [Abstract][Full Text] [Related]
18. The true role of mRECIST guideline: does it really estimate viable tumor or merely improve accuracy in hepatocellular carcinoma response evaluation?
Liu Q; Li A; Sun S; Luo R; Chen F
J BUON; 2014; 19(2):398-405. PubMed ID: 24965398
[TBL] [Abstract][Full Text] [Related]
19. Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplantability and recurrence rate.
Cescon M; Cucchetti A; Ravaioli M; Pinna AD
J Hepatol; 2013 Mar; 58(3):609-18. PubMed ID: 23041304
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of RECIST and mRECIST criteria as prognostic factors in patients undergoing repeated iodized oil chemoembolization of intermediate stage hepatocellular carcinoma.
Hyun D; Shin SW; Cho SK; Park KB; Park HS; Choo SW; Do YS; Choo IW; Shin JW; Lim SJ
Acta Radiol; 2015 Dec; 56(12):1437-45. PubMed ID: 25480473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]